Literature DB >> 17898795

Pulmonary delivery of adenovirus vector formulated with dexamethasone-spermine facilitates homologous vector re-administration.

A R Price1, M P Limberis, J M Wilson, S L Diamond.   

Abstract

Gene transfer to lung has been hindered by inflammatory and immunological responses activated to the gene-transfer agent or transgene products. In prior work, adenovirus vector delivered to the lung with the cationic glucocorticoid, dexamethasone-spermine (DS) had improved targeting to conducting airway epithelium and reduced cellular infiltration. In this study, the effect of formulation on homologous adenovirus vector re-administration was studied in C57Bl/6 mice. Formulation of an adenovirus vector expressing LacZ with DS/dioleoylphosphatidylethanolamine (DOPE) delivered at day 0 allowed re-administration of adenovirus vector expressing alkaline phosphatase at day 21. Formulation with 3beta [N-(N', N'-dimethylaminoethane) carbamoy] cholesterol (DC-Chol) DC-cholesterol (DC-Chol))/DOPE or dexamethasone in the first dosing at day 0 resulted in moderate alkaline phosphatase expression at day 24. Neutralizing antibodies against adenovirus vector in serum at day 28 were greatly reduced by all three formulations in mice receiving a single dose of adenovirus at day 0. Also, homologous adenovirus vector re-administration at day 14 produced less neutralizing antibody at day 28 when adenovirus was formulated with DS/DOPE at day 0. The use of DS/DOPE at day 0 dramatically reduced CD4 and CD8 T-cell infiltration in mice receiving adenovirus at day 0 followed by vector re-administration at day 14. Transgene-specific T-cell activation was markedly reduced by the DC-Chol/DOPE formulation. Overall, DS/DOPE) facilitated homologous vector re-administration through a combination of liposomal and glucocorticoid mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17898795     DOI: 10.1038/sj.gt.3303031

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  7 in total

Review 1.  Advances in cell and gene-based therapies for cystic fibrosis lung disease.

Authors:  Mayumi Oakland; Patrick L Sinn; Paul B McCray
Journal:  Mol Ther       Date:  2012-02-28       Impact factor: 11.454

2.  Novel cationic lipids with enhanced gene delivery and antimicrobial activity.

Authors:  David E Fein; Robert Bucki; Fitzroy Byfield; Katarzyna Leszczynska; Paul A Janmey; Scott L Diamond
Journal:  Mol Pharmacol       Date:  2010-06-23       Impact factor: 4.436

3.  S-Nitrosothiol-modified nitric oxide-releasing chitosan oligosaccharides as antibacterial agents.

Authors:  Yuan Lu; Anand Shah; Rebecca A Hunter; Robert J Soto; Mark H Schoenfisch
Journal:  Acta Biomater       Date:  2014-10-25       Impact factor: 8.947

4.  Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Authors:  Sergey S Seregin; Daniel M Appledorn; Aaron J McBride; Nathaniel J Schuldt; Yasser A Aldhamen; Tyler Voss; Junping Wei; Matthew Bujold; William Nance; Sarah Godbehere; Andrea Amalfitano
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

5.  Cationic lipid formulations alter the in vivo tropism of AAV2/9 vector in lung.

Authors:  David E Fein; Maria P Limberis; Sean F Maloney; Jack M Heath; James M Wilson; Scott L Diamond
Journal:  Mol Ther       Date:  2009-07-28       Impact factor: 11.454

Review 6.  Progress and prospects: prospects of repeated pulmonary administration of viral vectors.

Authors:  P L Sinn; E R Burnight; P B McCray
Journal:  Gene Ther       Date:  2009-07-30       Impact factor: 5.250

Review 7.  Strategies to overcome host immunity to adenovirus vectors in vaccine development.

Authors:  Erin E Thacker; Laura Timares; Qiana L Matthews
Journal:  Expert Rev Vaccines       Date:  2009-06       Impact factor: 5.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.